Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Update

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 455,500 shares, a growth of 209.2% from the April 30th total of 147,300 shares. Approximately 1.3% of the shares of the company are sold […]

Related Keywords

,Corvus Pharmaceuticals Inc ,News Ratings For Corvus Pharmaceuticals Daily ,Discovery Capital Management ,Renaissance Technologies ,Cantor Fitzgerald ,Vanguard Group Inc ,Corvus Pharmaceuticals Stock Performance ,Hedge Funds Weigh In On Corvus Pharmaceuticals ,Nasdaq ,Corvus Pharmaceuticals ,Get Rating ,Capital Management ,Two Sigma Advisers ,Sigma Advisers ,Adenosine Production Inhibitor ,Corvus Pharmaceuticals Daily ,Nasdaq Crvs ,Ccrvs ,Medical ,Stocks ,Options ,Put ,Call ,